₿1 = $68,799.75▼ 2.43%
LIXTE Biotechnology Holdings, Inc.
LIXT🇺🇸Reserve
$2.74
As of 2026-03-20 (delayed)
Clinical-stage biopharmaceutical company developing cancer therapies based on PP2A inhibitors. Adopted a corporate treasury policy in August 2025 to allocate up to 50% of treasury holdings to cryptocurrency, purchasing 10.5 BTC and 300 ETH with existing cash reserves.
Reserves
BTC Reserve
10.5 BTC
Fiat Reserve
2.89M USD
Total Reserve
3.61M USD
Shares outstanding
5.70M
Key Metrics
Total outstanding
0.00 USD
Market cap
15.63M USD
mNAV
21.64x
Amplification
0.0%
Leverage
0.0%
Avg-weighted maturity
—
In-the-money
—
Dilution if full conversion
0.0%
Stacking
Sats/Share
184
Convertibles(0)
Convertibles(0)
No active convertibles.
Preferred instruments(0)
Preferred instruments(0)
No active Preferreds.
Other debt(0)
Other debt(0)
No active other debt.